Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celleron gets rights to AstraZeneca's HDAC inhibitor

Executive Summary

Celleron Therapeutics (targeted cancer treatments) received exclusive worldwide development and commercialization rights to AstraZeneca's lead histone deacetylase (HDAC) inhibitor AZD9468, which it will develop in conjunction with a tumor biomarker technology for personalized cancer care.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register